Plain-English translation of NCT06514508 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether Motixafortide (BL-8040), when combined with a standard medication called G-CSF, helps doctors collect more of your own stem cells for transplant. Multiple myeloma is a blood cancer, and stem cell transplants are an important treatment. This study will compare the new medication to a placebo (inactive treatment) to see if it makes the stem cell collection process work better.
Collecting enough stem cells from patients with multiple myeloma can be challenging, and not all patients respond well to current collection methods. This medication is being tested to see if it can improve the success of stem cell collection, which would help more patients get the transplant they need.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication Motixafortide plus G-CSF, or a placebo plus G-CSF. You won't know which group you're in. Over several days, you'll receive injections to mobilize your stem cells into your bloodstream, then undergo a procedure to collect them. Your blood will be tested regularly to monitor how well the treatment is working and to check for any side effects.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
China